Vanguard Group Inc Acorda Therapeutics Inc Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.55 - $1.0 $802 - $1,459	1,459 Added 0.92%	159,778 $94,000
Q4 2022 Feb 10, 2023	BUY	$0.52 - $0.77 $1,580 - $2,340	3,040 Added 1.96%	158,319 $121,000
Q3 2022 Nov 14, 2022	SELL	$0.29 - $0.53 $806 - $1,474	-2,782 Reduced 1.76%	155,279 $46,000
Q2 2022 Aug 12, 2022	SELL	$0.3 - $1.67 $55,045 - $306,418	-183,484 Reduced 53.72%	158,061 $73,000
Q3 2021 Nov 12, 2021	BUY	$3.36 - $4.79 $3,575 - $5,096	1,064 Added 0.31%	341,545 $1.57 Million
Q2 2021 Aug 13, 2021	BUY	$3.61 - $5.23 $1.23 Million - $1.78 Million	340,481 New	340,481 $1.62 Million

133K

Ticker ACOR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 24,338,400
Market Cap $6.33M
Description
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.